Drugs / AZD7295
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01097408 | Mar → May 2010 | — | Arrow Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00818129 | Dec 2008 → May 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00906256 Comparator | Apr → Jul 2009 | — | Arrow Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00781976 Comparator | Nov 2008 → Mar 2010 | hepatitis C virus infection | Arrow Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD7295 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00818129 ↗ |
| Modality | Small molecule | — CHEMBL4297353 ↗ |
| Route | Oral | “Multiple Oral Doses of AZD7295” NCT00781976 ↗ |